Completed NA INTERVENTIONAL 2-arm NCT05813132

BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus CEM (Carboplatin, Etoposide, Melphalan) in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

Sponsor: Rehab Werida

Conditions Lymphoma

Interventions BEAM Protocol CEM protocol

Updated 7 times since 2023 Last updated: Sep 1, 2024 Started: Nov 11, 2022 Primary completion: Dec 30, 2023 Completion: Dec 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05813132, this NA trial focuses on Lymphoma and remains completed. Sponsored by Rehab Werida, it has been updated 7 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Oct 2024 — Present [monthly]

Completed NA
Sep 2024 — Oct 2024 [monthly]

Completed NA
Aug 2024 — Sep 2024 [monthly]

Completed NA
Jul 2024 — Aug 2024 [monthly]

Completed NA
Feb 2024 — Jul 2024 [monthly]

Completed NA

▶ Show 2 earlier versions

Oct 2023 — Feb 2024 [monthly]

Completed NA

Status: Recruiting → Completed
May 2023 — Oct 2023 [monthly]

Recruiting NA

First recorded

Nov 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rehab Werida

Data source: Damanhour University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cairo, Egypt